Publications
There is a significant effort to implement personalized approaches to cancer treatment, tailoring therapeutic choices based on the genomic profile of each patient’s cancer. This manuscript describes the results of a study that explored gene expression and metabolic signatures in ovarian cancer to discover both markers of treatment response and potential therapeutic targets.
Arend RC, Scalise CB, Gordon ER, Davis AM, Foxall ME, Johnston BE, Crossman DK, Cooper SJ. Metabolic alterations and WNT signaling impact immune response in HGSOC. Clin Cancer Res. 2022 Jan 14;. doi: 10.1158/1078-0432.CCR-21-2984. [Epub ahead of print] PubMed PMID: 35031546
The limited effectiveness of chemotherapy has led to a long effort in the scientific and medical communities to identify alternative treatment strategies. This manuscript describes the results of a study that used genome-wide CRISPR screening to identify genes involved in resistance to chemotherapy in pancreatic cancer.
Ramaker, RC, Hardigan, AA, Gordon, ER, et al, Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition. BMC Cancer 21, 632 (2021). https://doi.org/10.1186/s12885-021-08388-1.
Classically, gene regulatory loci are thought to be bound by only a small subset of transcription factors. This manuscript presents results from a study that characterized regions of DNA with high numbers of transcription factor binding events, called high occupancy target (HOT) loci. By using two methods to find DNA binding associations across the genome, the group found about 15,000 HOT loci that could be bound by more than twenty-five percent of the DNA binding proteins assayed.
Ramaker RC, Hardigan AA, Goh ST, Partridge EC, Wold B, Cooper SJ, Myers RM. Dissecting the regulatory activity and sequence content of loci with exceptional numbers of transcription factor associations. Genome Res. 2020 Jul;30(7):939-950. doi: 10.1101/gr.260463.119. Epub 2020 Jul 2. PubMed PMID: 32616518; PubMed Central PMCID: PMC7397867.